FUSION PROTEIN COMPRISING CCL3 VARIANT AND USE THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS.

摘要

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3a or CCL33 is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3a or CCL33 in the CCL3 variant.